Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:91
  • preuzimanja u poslednjih 30 dana:22

Sadržaj

članak: 1 od 1  
2020, vol. 70, br. 5, str. 297-309
Praktični aspekti u određivanju antikoagulantnog dejstva direktnih oralnih antikoagulantnih lekova
Univerzitet u Beogradu, Farmaceutski fakultet, Institut za medicinsku biohemiju + Klinički centar Srbije, Centar za medicinsku biohemiju, Beograd

e-adresavioleta.dopsaj@gmal.com
Ključne reči: DOAC; rivaroksaban; dabigatran; apiksaban; laboratorijsko praćenje
Sažetak
Nova generacija oralnih antikoagulantnih lekova omogućava direktnu inhibiciju FIIa ili FXa, i sve više zamenjuje klasične antikoagulanse u kliničkoj praksi za različita stanja. Ovi lekovi su označeni sa nekoliko akronima, uključujući NOAC, DOAC, i odnose se na nove (ne-vitamin K antagoniste) i direktne oralne antikoagulanse, a trenutno uključuju dabigatran (FIIa inhibitor), i rivaroksaban, apiksaban i edoksaban (FXa inhibitori) . Direktni oralni antikoagulantni lekovi odobreni su za prevenciju moždanog udara kod pacijenata sa ne-valvularnom atrijalnom fibrilacijom i za prevenciju i lečenje venskog tromboembolizma. "Mantra" da direktni oralni antikoagulantni lekovi ne zahtevaju laboratorijsko praćenje ne može se prihvatiti u mnogim kliničkim situacijama. Štaviše, pošto ovi lekovi "ne zahtevaju" laboratorijsko praćenje, neki kliničari su to prihvatili kao da ne utiču na testove u hemostazi. Postoji više situacija u kojima je potrebno rutinsko i hitno određivanje DOAC-a, pri čemu će se broj laboratorijskih zahteva povećavati u budućnosti jer sve više zamenjuju konvencionalne antikoagulanse za sve veći broj indikacija, kod sve većeg broja pacijenata. Glavni cilj ovog rada je da odgovori na praktična pitanja u opštem laboratorijskom ispitivanju DOAC-a, kao i da pomogne u uklanjanju i smanjenju dijagnostičkih grešaka povezanih sa ispitivanjem hemostaze. Testovi za kvantifikaciju DOAC-a moraju biti dostupni u medicinskim centrima 24 sata, kako bi se olakšalo optimalno lečenje u uslovima kada stvari pođu po zlu ili u hitnim slučajevima trenutnog ukidanja antikoagulantne terapije ili odgovarajuće primene specifičnog antidota.
Reference
Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., Palareti, G. (2012) American College of Chest Physicia: Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 9th ed: 41(Suppl. 2):e44S-88S
Antonijević, N.M., Živković, I.D., Jovanović, L.M., Matić, D.M., Kočica, M.J., Mrdović, I.B., Kanjuh, V.I., Ćulafić, M.D. (2017) Dabigatran: Metabolism, Pharmacologic Properties and Drug Interactions. Current Drug Metabolism, 18(7): 1-14
Baglin, T. (2013) The role of the laboratory in treatment with new oral anticoagulants. Journal of Thrombosis and Haemostasis, 11(1): 122-128
Bauer, K.A. (2015) Targeted Anti-Anticoagulants. New England Journal of Medicine, 373(6): 569-571
Brieger, D., Curnow, J. (2014) Anticoagulation: A GP primer on the new oral anticoagulants. Aust Fam Physician, 43(5): 254-59
Child, C.G., Turcotte, J.G. (1964) Surgery and portal hypertension. Major Probl Clin Surg, 1: 1-85
Cuker, A., Siegal, D.M., Crowther, M.A., Garcia, D.A. (2014) Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants. Journal of the American College of Cardiology, 64(11): 1128-1139
Dale, B.J., Chan, N.C., Eikelboom, J.W. (2016) Laboratory measurement of the direct oral anticoagulants. British Journal of Haematology, 172(3): 315-336
Douxfils, J., Chatelain, C., Chatelain, B., Dogné, J.M., Mullier, F. (2013) Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide. Thromb Haemost, 110: 283-94
Douxfils, J., Mullier, F., Loosen, C., Chatelain, C., Chatelain, B., Dogné, J. (2012) Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thrombosis Research, 130(6): 956-966
Douxfils, J., Mullier, F., Robert, S., Chatelain, C., Chatelain, B., Dogné, J. (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays: Laboratory recommendations for monitoring of dabigatran etexilate. Thrombosis and Haemostasis, 107(05): 985-997
Favaloro, E.J., Adcock, F.D.M., Lippi, G. (2012) Pre-analytical Variables in Coagulation Testing Associated with Diagnostic Errors in Hemostasis. Laboratory Medicine, 43(2): 1.2-10
Favaloro, E.J., Mcdonald, D., Lippi, G. (2009) Laboratory investigation of thrombophilia: The good, the bad, and the ugly. Seminars in Thrombosis and Hemostasis, 35(07): 695-710
Gosselin, R.C., Adcock, D.M. (2016) The laboratory's 2015 perspective on direct oral anticoagulant testing. Journal of Thrombosis and Haemostasis, 14(5): 886-893
Gouin-Thibault, I., Delavenne, X., Blanchard, A., Siguret, V., Salem, J.E., Narjoz, C., Gaussem, P., Beaune, P., Funck-Brentano, C., Azizi, M., Mismetti, P., Loriot, M.A. (2017) Interindividual variability in dabigatran and rivaroxaban exposure: Contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis, 15(2): 273-283
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, J.A., Kirchhof, P. (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 17(10): 1467-1507
Levy, J.H., Ageno, W., Chan, N.C., Crowther, M., Verhamme, P., Weitz, J.I. (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 14(3): 623-627
Lippi, G., Favaloro, E.J. (2015) Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): Is there consensus?. Clinical Chemistry and Laboratory Medicine (CCLM), 53(2): 185-97
Lippi, G., Plebani, M. (2016) Laboratory economics: Risk or opportunity?. Clinical Chemistry and Laboratory Medicine (CCLM), 54(11): 1701-1704
Michels, W.M., Grootendorst, D.C., Verduijn, M., Elliott, E.G., Dekker, F.W., Krediet, R.T. (2010) Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clinical journal of the American Society of Nephrology, 5(6): 1003-9
Moore, G.W. (2014) Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants. Seminars in Thrombosis and Hemostasis, 40(02): 163-171
Pengo, V., Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Poli, D., Testa, S., Tiraferri, E., Tosetto, A., Tripodi, A., Manotti, C. (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation: A consensus document of the Italian Federation of Thrombosis Center (FCSA). Thrombosis and Haemostasis, 106(11): 868-876
Pollack, C.V.Jr., Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., Dubiel, R., Huisman, M.V., Hylek, E.M., Kamphuisen, P.W., Kreuzer, J., Levy, J.H., Sellke, F.W., Stangier, J. (2015) Idarucizumab for Dabigatran Reversal. New England Journal of Medicine, 373(6): 511-520
Pugh, R.N.H., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R. (1973) Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery, 60(8): 646-649
Samuelson, B.T., Cuker, A., Siegal, D.M., Crowther, M., Garcia, D.A. (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: A systematic review. Chest, 151(1): 127-138
Tripodi, A. (2013) The Laboratory and the New Oral Anticoagulants. Clinical Chemistry, 59(2): 353-362
Tripodi, A. (2013) The laboratory and the direct oral anticoagulants. Blood, 121(20): 4032-4035
Tripodi, A. (2012) Interference of new oral anticoagulants with frequently used coagulation tests. Clinical Chemistry and Laboratory Medicine (CCLM), 50(9): 1501-1504
Tripodi, A., di Iorio, G., Lippi, G., Testa, S., Manotti, C. (2012) Position paper on laboratory testing for patients taking new oral anticoagulants: Consensus document of FCSA, SIMeL, SIBioC and CISMEL1. Clinical Chemistry and Laboratory Medicine, 50(12): 462-70
Tripodi, A., Braham, S., Scimeca, B., Moia, M., Peyvandi, F. (2018) How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. Polish Archives of Internal Medicine, 128(6): 379-385
van Blerk, M., Bailleul, E., Chatelain, B., i dr. (2015) Influence of dabigatran and rivaroxaban on routine coagulation assays: A nationwide Belgian survey. Thromb Haemost, 113: 154-64
Weitz, J.I., Eikelboom, J.W. (2016) Urgent Need to Measure Effects of Direct Oral Anticoagulants. Circulation, 134(3): 186-188
 

O članku

jezik rada: engleski
vrsta rada: pregledni članak
DOI: 10.5937/arhfarm2005297D
objavljen u SCIndeksu: 13.11.2020.
metod recenzije: jednostruko anoniman
Creative Commons License 4.0